Association of adiponectin with peripheral arterial disease and mortality in nondiabetic hemodialysis patients: Long-term follow-up data of 7 years

Journal of Research in Medical Sciences

Volumn 21, Issue 1, 2016, Pages

  Zhou, Yijun ^a   Zhang, Jiwei ^a   Zhang, Weiming ^a   Ni, Zhaohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adiponectin; ankle brachial index; atherosclerosis; follow up studies

Indexed keywords

EID: 85026476797     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: 10.4103/1735-1995.184000     Document Type: Article

References (31)

1. U.S. Renal Data System. USRDS 2013 Annual Data Report (ADR) Atlas. Atlas of End-Stage Renal Disease. Ch. 4. Cardiovascular Disease; 2013.
2. Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol 2010;55:898-903.
3. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng XY, et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: Proteomic profiling and clinical studies. Circulation 2007;116:1396-403.
4. Otsubo S, Kitamura M, Wakaume T, Yajima A, Ishihara M, Takasaki M, et al. Association of peripheral artery disease and long-term mortality in hemodialysis patients. Int Urol Nephrol 2012;44:569-73.
5. Al Thani H, El-Menyar A, Hussein A, Sadek A, Sharaf A, Singh R, et al. Prevalence, predictors, and impact of peripheral arterial disease in hemodialysis patients: A cohort study with a 3-year follow-up. Angiology 2013;64:98-104.
6. Knudson JD, Dick GM, Tune JD. Adipokines and coronary vasomotor dysfunction. Exp Biol Med (Maywood) 2007;232:727-36.
7. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2009;302:179-88.
8. Antoniades C, Antonopoulos AS, Tousoulis D, Ste-fanadis C. Adiponectin: From obesity to cardiovascular disease: Etiology and Pathophysiology. Obes Rev 2009;10:269-79.
9. Dieplinger B, Poelz W, Haltmayer M, Mueller T. Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease. Clin Chem Lab Med 2006;44:830-3.
10. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005;111:747-53.
11. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
12. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534-9.
13. D í e z J J, E s t r a d a P, B a j o M A, F e r n á n d e z - R e y e s M J, Grande C, del Peso G, et al. High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol 2009;30:244-52.
14. Tsigalou C, Chalikias G, Kantartzi K, Tziakas D, Kampouromiti G, Vargemezis V, et al. Differential effect of baseline adiponectin on all-cause mortality in hemodialysis patients depending on initial body mass index. Long-term follow-up data of 4.5 years. J Ren Nutr 2013;23:45-56.
15. Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009;76:567-75.
16. Rhee CM, Nguyen DV, Moradi H, Brunelli SM, Dukkipati R, Jing J, et al. Association of adiponectin with body composition and mortality in hemodialysis patients. Am J Kidney Dis 2015;66:313-21.
17. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
18. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Critical issues in peripheral arterial disease detection and management: A call to action. Arch Intern Med 2003;163:884-92.
19. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: Cross-sectional study. Atherosclerosis 2004;172:95-105.
20. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, et al. Chronic renal insufficiency cohort (CRIC) study: Baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009;4:1302-11.
21. Ono K, Tsuchida A, Kawai H, Matsuo H, Wakamatsu R, Maezawa A, et al. Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol 2003;14:1591-8.
22. Chen SC, Su HM, Mai HC, Chen JH, Chen CY, Chang JM, et al. Associated risk factors for abnormal ankle-brachial index in hemodialysis patients in a hospital. Kaohsiung J Med Sci 2008;24:473-80.
23. Kanbay M, Afsar B, Gusbeth-Tatomir P, Covic A. Arterial stiffness in dialysis patients: Where are we now? Int Urol Nephrol 2010;42:741-52.
24. Paraskevas KI, Kotsikoris I, Koupidis SA, Tzovaras AA, Mikhailidis DP. Cardiovascular events in chronic dialysis patients: Emphasizing the importance of vascular disease prevention. Int Urol Nephrol 2010;42:999-1006.
25. Liu JH, Chen JY, Lin SY, Lin HH, Ting IW, Liang CC, et al. Comparing Survival between peritoneal dialysis and hemodialysis patients with subclinical peripheral artery disease: A 6-year follow-up. Int J Med Sci 2013;10:434-40.
26. Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol 2013;33:2-13.
27. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
28. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007;117:375-86.
29. Lim PS, Hu CY, Wu MY, Wu TK, Chang HC. Plasma adiponectin is associated with ankle-brachial index in patients on haemodialysis. Nephrology (Carlton) 2007;12:546-52.
30. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-41.
31. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS; HEMO Study Group. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008;23:2619-28.